Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025

Efficacy and Safety of Momelotinib in Myelofibrosis: A Systematic Review and Meta-Analysis With a Focus on Anemia Outcomes.

View Full Paper
Ask AI
Bookmark
Share

Authors

JAJowan Al‐NusairMarshall HealthMAMo’men Aldalal’ahYarmouk UniversityMAMohammad AlqudahJordan University of Science and Technology

Discussion

Loading...

Member takes

Implication

Systematic review and meta-analysis show momelotinib improves anemia in myelofibrosis, indicating its potential over other JAK inhibitors.

Key Points

  • Momelotinib improved anemia-related outcomes in myelofibrosis without increasing adverse events.
  • The meta-analysis revealed that momelotinib increased transfusion independence with an odds ratio of 2.09.
  • Six studies, including three randomized controlled trials, were included following PRISMA guidelines for systematic review.
  • These findings suggest momelotinib may provide significant anemia benefits, emphasizing the need for further research.

Cite This Study

Al‐Nusair et al. (2025) studied this question.

synapsesocial.com/papers/68c23c20b210217d64787e49https://doi.org/10.14740/jh2094
View Full Paper
Ask AI
Bookmark
Share